The 6 key players our Menopause Treatment report profiles, and other companies free public records show in this market.
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Astellas Pharma Inc. | — | 264 reports |
| 2 | Bayer AG |
bayer.com (opens in a new tab) | 1,320 reports |
| 3 | Pfizer Inc. |
pfizer.com (opens in a new tab) | 2,310 reports |
| 4 | Novo Nordisk A/S |
novo.com (opens in a new tab) | 495 reports |
| 5 | TherapeuticsMD | — | 66 reports |
| 6 | Mithra Pharmaceuticals | — | 66 reports |
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
| SRI International |
|
| Zydus Lifesciences | |
Amneal Pharmaceuticals, Inc |
|
| Stratpharma AG |
|
| Mucosa Innovations, S.L. |
|
| Wyeth Pharmaceuticals | |
| Mylan N.V. | |
| Novitium Pharma | |
| Epic Systems Corporation | |
| Encube | |
| PH Health | |
Glenmark Pharmaceuticals |
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Companies leading the most active studies found with this market's trial search, worldwide (key players included).
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.